Journal of Clinical Oncology· 2018Q1· Clinical trial
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
- 1,330citations
- Q1SCImago
- 2018year
Short summary
In cancer patients with venous thromboembolism (VTE), the oral factor Xa inhibitor rivaroxaban significantly reduced VTE recurrence by 57% over 6 months compared to standard low molecular weight heparin (dalteparin).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Internal Medicine
Internal MedicineMedicine